278 related articles for article (PubMed ID: 36707619)
1. Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations.
Sembill S; Ampatzidou M; Chaudhury S; Dworzak M; Kalwak K; Karow A; Kiani A; Krumbholz M; Luesink M; Naumann-Bartsch N; De Moerloose B; Osborn M; Schultz KR; Sedlacek P; Giona F; Zwaan CM; Shimada H; Versluijs B; Millot F; Hijiya N; Suttorp M; Metzler M
Leukemia; 2023 Mar; 37(3):505-517. PubMed ID: 36707619
[TBL] [Abstract][Full Text] [Related]
2. An Update on the Management of Advanced Phase Chronic Myeloid Leukemia.
Short NJ; Senapati J; Jabbour E
Curr Hematol Malig Rep; 2023 Dec; 18(6):234-242. PubMed ID: 37651057
[TBL] [Abstract][Full Text] [Related]
3. Blast and accelerated phase CML: room for improvement.
How J; Venkataraman V; Hobbs GS
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):122-128. PubMed ID: 34889372
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
Xu LP; Xu ZL; Zhang XH; Chen H; Chen YH; Han W; Chen Y; Wang FR; Wang JZ; Wang Y; Yan CH; Mo XD; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1080-1086. PubMed ID: 26995693
[TBL] [Abstract][Full Text] [Related]
6. Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity.
Copland M
Br J Haematol; 2022 Dec; 199(5):665-678. PubMed ID: 35866251
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Factors for Outcomes of Allogeneic HSCT for Children and Adolescents/Young Adults With CML in the TKI Era.
Shimada H; Tanizawa A; Kondo T; Nagamura-Inoue T; Yasui M; Tojo A; Muramatsu H; Eto T; Doki N; Tanaka M; Sato M; Noguchi M; Uchida N; Takahashi Y; Sakata N; Ichinohe T; Hashii Y; Kato K; Atsuta Y; Ohashi K;
Transplant Cell Ther; 2022 Jul; 28(7):376-389. PubMed ID: 35447373
[TBL] [Abstract][Full Text] [Related]
8. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
[TBL] [Abstract][Full Text] [Related]
9. Impact of frontline treatment approach on outcomes of myeloid blast phase CML.
Saxena K; Jabbour E; Issa G; Sasaki K; Ravandi F; Maiti A; Daver N; Kadia T; DiNardo CD; Konopleva M; Cortes JE; Yilmaz M; Chien K; Pierce S; Kantarjian H; Short NJ
J Hematol Oncol; 2021 Jun; 14(1):94. PubMed ID: 34130720
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia.
Senapati J; Jabbour E; Kantarjian H; Short NJ
Leukemia; 2023 Jan; 37(1):5-17. PubMed ID: 36309558
[TBL] [Abstract][Full Text] [Related]
11. Outcomes Following Bone Marrow Transplantation in Children With Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors.
Shulman DS; Lee MA; Lehmann LE; Margossian SP
J Pediatr Hematol Oncol; 2016 Nov; 38(8):610-614. PubMed ID: 27403776
[TBL] [Abstract][Full Text] [Related]
12. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
Egan DN; Beppu L; Radich JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
[TBL] [Abstract][Full Text] [Related]
13. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
15. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.
Chhabra S; Ahn KW; Hu ZH; Jain S; Assal A; Cerny J; Copelan EA; Daly A; DeFilipp Z; Gadalla SM; Gale RP; Ganguly S; Hamilton BK; Hildebrandt GC; Hsu JW; Inamoto Y; Kanate AS; Khoury HJ; Lazarus HM; Litzow MR; Nathan S; Olsson RF; Pawarode A; Ringden O; Rowe JM; Saad A; Savani BN; Schouten HC; Seo S; Shah NN; Solh M; Stuart RK; Ustun C; Woolfrey AE; Yared JA; Alyea EP; Kalaycio ME; Popat U; Sobecks RM; Saber W
Blood Adv; 2018 Nov; 2(21):2922-2936. PubMed ID: 30396912
[TBL] [Abstract][Full Text] [Related]
16. B-Lymphoid Blast Phase-Chronic Myeloid Leukemia: Current Therapeutics.
Yohannan B; George B
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233138
[TBL] [Abstract][Full Text] [Related]
17. Recent progress in the management of pediatric chronic myeloid leukemia.
Shima H; Shimada H
Int J Hematol; 2023 Feb; 117(2):182-187. PubMed ID: 36574169
[TBL] [Abstract][Full Text] [Related]
18. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
19. Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
Brioli A; Lomaia E; Fabisch C; Sacha T; Klamova H; Morozova E; Golos A; Ernst P; Olsson-Stromberg U; Zackova D; Nicolini FE; Bao H; Castagnetti F; Patkowska E; Mayer J; Hirschbühl K; Podgornik H; Paczkowska E; Parry A; Ernst T; Voskanyan A; Szczepanek E; Saussele S; Franke GN; Kiani A; Faber E; Krause S; Casado LF; Lewandowski K; Eder M; Anhut P; Gil J; Südhoff T; Hebart H; Heibl S; Pfirrmann M; Hochhaus A; Lauseker M
Leukemia; 2024 May; 38(5):1072-1080. PubMed ID: 38548962
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]